Abstract
The introduction of cyclosporin into maintenance therapy for kidney-transplant recipients has played an important part in the improvement of graft survival reported worldwide [1]. Cyclosporin is potentially toxic to various tissues including kidney, liver, endocrine pancreas, and nervous system, and its use is associated with hypertension [2]. Nevertheless, the capacity of cyclosporin treatment to increase graft survival has been recognised for a long time. Optimum doses and trough blood concentrations of cyclosporin have been empirically evolved so as to cause the least kidney toxicity. However, cyclosporin has other potential side-effects related to its immunosuppressant properties, including the occurrence of infections and tumours. The magnitude of these effects may also vary with dose and consequent trough blood concentrations. Thus, there is potential for improvement in dose schedules. In terms of reducing long-term complications of immunosuppression, such as cancers [3], kidney recipients are unlike other organ-graft recipients because long-term dialysis is a viable alternative.
This paper was first published in The Lancet 1998; 357: 623-28 (February 28), and is reprinted here by kind permission. © by The Lancet Ltd. 1998.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N. Engl. J. Med. 1986; 314: 1219–1225.
Bennett WM, De Mattos A, Meyer MM et al. Chronic cyclosporine nephropathy: the Achilles’ heel of immunosuppressive therapy. Kidney Int. 1996; 50: 1089–1100.
Sheil AGR, Disney APS, Mathew TH et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant. Proc. 1993; 25: 1383–1384.
Hourmant M, Taupin JL, Lemergie D et al. Azathioprine-cyclosporine A (CyA) double therapy versus CyA alone after the first rejection episode in kidney-transplanted patients under CyA: a randomized study. Transplant. Int. 1989; 2: 113–116.
Opeiz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation. 1994; 58: 443–446.
Hourmant M, Le Mauff B, Lemeur Y et al. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation: a pilot study. Transplantation. 1994: 58: 377–380.
Dantal J, Ninin E, Hourmant M et al. Anti-CD4 MoAb therapy in kidney transplantation: a pilot study in early prophylaxis of rejection. Transplantation. 1996; 62: 1502–1506.
Soulillou JP, Cantarovich D, Lemauff B et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulins for prophylaxis against rejection of renal allografts. N. Engl. J. Med. 1990; 322: 1175–1182.
Burcke JF, Pirsch JD, Ramos EL et al. A multicenter four year retrospective study in renal transplant recipients treated with cyclosporine. evidence for long term efficacy and safety. N. Engl. J. Med. 1994; 331: 358–363.
Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993; 44: 411–422.
European Multicenter Trial Group. Cyclosporin in cadaveric renal transplantation: 1 year follow-up of a multicentre trial. Lancet. 1983; ii: 986–989.
Kasiske BL, Heim-Duthoy KL, Ma JZ. Elective cyclosporine withdrawal after renal transplantation: a metaanalysis. JAMA. 1993; 269: 395–400.
Lindholm A, Ohlman S, Albrechtsen D et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation. 1993; 56: 307–315.
Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients In: Tearaski PI, Cecka JM eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1994; 99–109.
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993; 342: 1514–1516.
Kovarik JM, Mueller EA, Van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation. 1994; 58: 658–663.
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61: 1029–1037.
Vincenti F, Laskow DA, Neylan JF et al. One-year-follow-up of an open-label trial of FK 506 for primary kidney transplantation. Transplantation. 1996; 61: 1576–1581.
Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant. Proc. 1997; 29: 36–41.
Morris RE. Beware: shifting paradigms ahead. Lancet. 1996; 348 (suppl. II): II26.
Dilling MB, Dias P, Shapiro DN et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the insulin like growth factor receptor. Cancer Res. 1994; 54: 903–908.
Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int. J. Cancer. 1994; 57: 568–573.
Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years-early events affecting transplant success. Transplantation. 1992; 53: 59–64.
London NJ, Farmery SM, Will EJ et al. Risk of neoplasia in renal transplant patients. Lancet. 1995; 346: 403–406.
Blohme I, Larkö O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation. 1984; 37: 165–167.
Confavreux C, Saddier P, Grimaud J et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996; 46: 1607–1612.
West M, Sutherland D, Matas A. Kidney transplant recipients who die with functioning grafts. Transplantation. 1996; 62: 1019–1030.
Morris JDH, Eddleston ALWF, Crook T. Viral infection and cancer. Lancet. 1995; 346: 754–758.
Buccianti G, Ravasi B, Cresseri D et al. Cancer in patients on renal replacement therapy in Lombardy, Italy. Lancet. 1996; 347: 59–60.
Stewart T, Tsai SCJ, Grayson H et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995; 346: 796–798.
Editor information
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Dantal, J. et al. (1999). Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_16
Download citation
DOI: https://doi.org/10.1007/978-94-011-4643-2_16
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5960-2
Online ISBN: 978-94-011-4643-2
eBook Packages: Springer Book Archive